# WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease

> **NCT04551456** · PHASE2 · UNKNOWN · sponsor: **Navy General Hospital, Beijing** · enrollment: 300 (estimated)

## Conditions studied

- Coronary Artery Disease

## Interventions

- **BIOLOGICAL:** Intravenous infusion human umbilical Wharton's jelly-derived mesenchymal stem Cell or placebo PBS

## Key facts

- **NCT ID:** NCT04551456
- **Lead sponsor:** Navy General Hospital, Beijing
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-30
- **Primary completion:** 2021-12-30
- **Final completion:** 2022-12-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2020-09-16

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04551456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04551456, "WJMSCs Anti-inflammatory Therapy in Coronary Artery Disease". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04551456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*